

Relation between blood CD49d and muscle ultrasonography in children with Duchenne Muscular Dystrophy

Thesis

Submitted for partial fulfillment of Master degree
in Pediatrics

Presented by

Fatma Hasan Hasan Besar

M.B,B.CH. (2011)
Ain Shams University

Under Supervision of

Prof. Sahar Mohamed Ahmed Hassanein

Professor of Pediatrics
Faculty of Medicine, Ain Shams University

Prof. Hanaa Mohammed El Sayed Afifi

Professor of Clinical Pathology
Faculty of Medicine, Ain Shams University

Dr. Hossam Moussa El-Sayed Sakr

Associate Professor of Radiodiagnosis
Faculty of Medicine, Ain Shams University

*Faculty of Medicine
Ain-Shams University
2018*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم الكبير

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgments

*First and forever, thanks to **Allah**, Almighty for giving me the strength and faith to complete my thesis and for everything else.*

*My deepest gratitude and profound appreciation to **Prof. Sahar Mohamed Ahmed Hassanein**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her meticulous observation, her sincere guidance, support, patience and endurance despite her multitude of tasks and burden. I really have the honor to complete this work under her supervision.*

*I would like as well to have the opportunity to express my respect and gratitude to **Prof. Hanaa Mohammed El Sayed Afifi**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her endless patience, untiring help, fruitful advice and supervision throughout the period of this study.*

*I owe a great debt of gratitude to **Dr. Hossam Moussa El-Sayed Sakr**, Associate Professor of Radiodiagnosis, Faculty of Medicine, Ain Shams University, for the time and efforts he has devoted to accomplish this work.*

*Finally I would like to express my deepest and greatest thanks and gratitude to my mother and my wife and **Family**, for their help, support, patience, endurance, understanding and encouragement to accomplish this work.*

 **Fatma Hasan Hasan Besar**

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	i
List of Tables.....	ii
List of Figures	iii
Introduction	1
Aim of the Study	4
Review of Literature	
Duchenne Muscle Dystrophy	5
Diagnostic Ultrasound in Duchenne Muscular Dystrophy	58
Role of VLA-4 (CD49d/CD29) on T cell traffick in Dnchenne Muscular Dystrophy	65
Patients and Methods.....	73
Results.....	87
Discussion	111
Summary	123
Conclusion.....	126
Recommendations	127
References	128
Arabic Summary	—

List of Abbreviations

<i>Abbr.</i>	<i>Full-term</i>
DMD	: Duchenne Muscle Dystrophy
DGC	: Dystrophin-associated glycoprotein complex
MUS	: Muscle ultrasound
QMUS	: Quantitative muscle ultrasound
KD	: Kilodaltons
n NOS	: Neuronal nitric oxide synthase
I NOS	: Inducible nitric oxide synthase
SDB	: Sleep-disordered breathing
REM	: Rrapid eye movement sleep
WAIS	: Wechsler Adult Intelligence Scale
IQ	: Intelligence Quotient
CK	: Creatine kinase
EMG	: Electromyography
ATPase	: Adenosine triphosphatase
MLPA	: Multiplex ligation-dependent probe amplification
PCR	: Polymerase chain reaction

List of Abbreviations

FISH	: Fluorescence in situ hybridization
DHPLC	: Denaturing high performance liquid chromatography
SCAIP	: Single-condition amplification internal primer sequencing
DGGE	: Denaturing gradient gel electrophoresis
DOVAMK-S	: Detection of virtually all mutations - single-strand
DCM	: Dilated cardiomyopathy
NIPPV	: Intermittent positive pressure ventilation
DXA	: Dual energy x-ray absorptiometry
25OHD	: 25-hydroxyvitamin D
AAN	: American Academy of Neurology
rAAV	: Recombinant adeno-associated viral
FDA	: Food and Drug Administration
EMG	: Electromyography
CT	: Computed tomography
MRI	: Magnetic resonance imaging
ECM	: Extracellular matrix
VCAM-1	: Vascular cell adhesion molecule-1
FN	: Fibronectin
CBC	: Complete blood Count
ELISA	: Enzyme-linked immunosorbent assay
ROM	: Range of motion
10MWT	: Ten Meters Walk Test
QBA	: Quantitative backscatter analysis
GSL	: Grayscale levels

List of Tables

Table No.	Title	Page No.
Table (1):	Muscle power grading.....	85
Table (2):	Demographic and anthropometric of patients and controls.	87
Table (3):	Laboratory data of studied groups.	90
Table (4):	Descriptive statistics of complications of DMD (cardiac involvement, pulmonary function, ten meter test) and steroid therapy among the studied patients.....	91
Table (5):	Descriptive data regarding intensity mean value of examined muscles by ultrasound among the patients group:.....	94
Table (6):	Comparison between patients and controls as regards demographic and anthropometric data.	95
Table (7):	Comparison between patients and controls as regards laboratory data.	96
Table (8):	Comparison of CD 49 according to disease duration.....	98
Table (9):	Comparison of CD 49 according to age group	99
Table (10):	Comparison of CD 49 according to ten meter test category	100
Table (11):	Comparison of CD 49 according to progression in non ambulant patients	101

List of Tables

Table (12):	Comparison of CD 49 according to steroid therapy.....	102
Table (13):	Comparison of CD 49 according to cardiac involvement.....	103
Table (14):	Comparison of CD 49 according to pulmonary function.....	104
Table (15):	Diagnostic performance of CD 49 for the identification of established Duchenne muscular dystrophy.....	105
Table (16):	Correlation between CD49d and TLC.....	106

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	The dystrophin-associated protein complex (DPC) in skeletal muscle.....	7
Figure (2):	The Characteristic traits of Duchenne	14
Figure (3):	Typical DMD disease progression.....	17
Figure (4):	Muscle biopsy of DMD	24
Figure (5):	Normal dystrophin immunostaining of muscle	25
Figure (6):	Algorithm for the diagnosis of Duchenne and Becker muscular dystrophy	26
Figure (7):	Example of exon skipping in Duchenne muscular dystrophy (DMD) patient.....	51
Figure (8):	Summary of the wide range of approaches being used to treat Duchenne muscular dystrophy.....	56
Figure (9):	Interactions between ultrasound beam and normal and pathological tissues	60
Figure (10):	Activated autoreactive T cells expressing VLA-4 adhere to endothelium via interactions with VCAM and enter into the tissue.....	72
Figure (11):	Pie chart showing frequency of age category among patients group.....	89
Figure (12):	Pie chart showing frequency of disease duration category in patients.....	89

List of Figures

Figure (13): Pie chart showing cardiac involvement among patients group.....	92
Figure (14): Pie chart showing frequency of steroid therapy among patients group.....	92
Figure (15): Pie chart showing frequency of pulmonary function among patients group.	93
Figure (16): Pie chart showing ten meter test among patients group.....	93
Figure (17): Pie chart showing progression in non ambulant patients.	94
Figure (18): Mean Hb of patients and controls	97
Figure (19): Mean TLC of patients and controls	97
Figure (20): Mean CD 49 of patients and controls	98
Figure (21): Mean CD 49 according to disease duration	99
Figure (22): Mean CD 49 according to age group	100
Figure (23): Mean CD 49 of ambulant and non ambulant patients	101
Figure (24): Mean CD 49 of slow and rapid progressor in non ambulant patients	102
Figure (25): Mean CD 49 according to steroid therapy.....	103
Figure (26): Mean CD 49 of normal Echo and dilated cardiomyopathy patients	104
Figure (27): Mean CD 49 according to pulmonary function	105

List of Figures

Figure (28): Diagnostic performance of CD 49 for the identification of established Duchenne muscular dystrophy	106
Figure (29): Correlation between CD49d and CPK.....	107
Figure (30): Correlation between age and ten meter test of the patients	108
Figure (31): Correlation between disease duration and ten meter test	109
Figure (32): Correlation between ten meter test in ambulant patient and total muscle ultra sound	110

Abstract

Background: Duchenne Muscular Dystrophy (DMD) an X-linked recessive disorder affecting 1 in 3500- 6000 male births. It is caused by the absence of functional dystrophin, due to mutations in the dystrophin gene. Although the cause of DMD is genetic, there is accumulating data suggesting that an immune response may play a role in pathophysiology of this disease and also contributes to disease progression in DMD patients. Alpha integrins (CD49d) can drive T cells to the site of inflammation favoring migration and adhesion to the muscle tissue and muscle damage by interacting more strongly with the fiber and extracellular matrix proteins. DMD patients are clinically heterogeneous and the functional defect cannot be correlated with genotype. Therefore, it is important to be able to define reliable noninvasive inflammatory biomarkers. **Methods:** A case control study was carried out at neurology outpatient clinic, Children's Hospital, Ain Shams University . The study included 20 male patient (mean age of 10.35 years), compared to 20 healthy children age, sex and socioeconomic matched served as control group. Enrolled subjects underwent peripheral blood sampling (for measuring CD49d, CBC and CPK), motor grading and muscle ultrasound. **Results:** Patients had a significant higher CD 49 levels than controls. Cutoff values was 0.250 with 90% sensitivity and 70% specificity. **Conclusions:** Our data indicates that CD49d expression in high levels involved in the inflammatory process seen in DMD patients.

Key words: blood CD49d, muscle ultrasonography, children, Duchenne Muscular Dystrophy

Introduction

Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disease of muscle characterized by a progressive loss of functional muscle mass and replacement with fibrofatty tissue (*Sussman and Michael, 2002*).

The incidence of DMD is approximately 1 in 3500 live male births (*Gulati et al., 2005*). It is caused by mutations in the *DMD* gene. This gene encodes a protein called dystrophin (*Blake et al., 2002*), which localizes to the cytoplasmic face of the sarcolemma (plasma membrane) of the skeletal muscle (*Ervasti , 2007*), forming one component of a large glycoprotein complex (dystrophin-associated glycoprotein complex). The majority of mutations are intragenic deletions, which account for 65-72% of all DMD patients (*Aartsma-Rus et al., 2006*). Point mutations, small deletions or insertions account for 20% of patients without deletions or duplications (*Prior and Bridgeman , 2005*).

The precise mechanism of how dystrophin deficiency leads to degeneration of muscle fibers remains unclear. Absence of dystrophin at the plasma membrane leads to delocalisation of dystrophin-associated proteins from the membrane, disruption of the cytoskeleton with resultant membrane instability and increased susceptibility to mechanical stress (*Deconinck et al., 2007*).

Duchenne muscular dystrophy is the most common fatal genetic disorder diagnosed in childhood, and it does shorten life. Because the muscle weakness increases gradually over the years, complications eventually develop. The breathing or heart problems usually become more serious for older teenagers or people in their 20s. In the past, most people with DMD did not live beyond their early 20s. Improvements in treatment have meant that life expectancy has increased. At present, average life expectancy for people with DMD is 27 years. However, there is a lot of individual variation in the severity of DMD and the individual life expectancy (*Kliegman et al., 2011*).

There is no cure for DMD at this time, but there continues to be a tremendous amount of research taking place across the world (*Jefferies et al., 2005*). Treatment aims to control symptoms to improve quality of life. Steroid drugs can slow the loss of muscle strength. They may be started when the child is diagnosed or when muscle strength begins to decline. Physical therapy is used to promote mobility and prevent contractures (*Finder et al., 2004*).

Ultrasound imaging has proved to be a useful, non invasive screening tool in the investigation of children with neuromuscular disease. Muscular dystrophies were associated with an increase in the intensity of echo reflected from the muscle substance, with corresponding loss of bone echo. Severity of changes on the scan did not relate to

functional disability, and some children had good function yet strikingly abnormal scan. the degree on the scan correlated with the degree of disruption of muscle architecture on biopsy (*Wattjes et al., 2010*). Muscle ultrasound (MUS) is potentially an attractive follow up tool for DMD because it reflects the severity of the dystrophic process without the need for invasive procedures, by quantifying echo intensity (i.e. mean grey level of muscle images) and muscle thickness (*Jansen et al., 2012*).

DMD patients are clinically heterogeneous and the functional defect cannot be correlated with genotype. Therefore, it is important to be able to define reliable noninvasive biomarkers to better define the disease progression (*Pinto-Mariz et al., 2015*). The non-invasive biomarkers obtained at early stages of the disease are found to be highly predictive for the loss of ambulation before 6 months of age. An elevation in the number of circulating CD49d^{hi} T cells is found to be strongly associated with the severe clinical form of the disease. This factor can be used as predictive tests for screening to separate them into groups with slow or fast disease progression before their inclusion into a therapy (*Barthélémy et al., 2014*).

Moreover, anti-CD49d peptides or antibodies can be used as a therapeutic approach to decrease inflammation-mediated tissue damage in DMD.